The purpose of Comparative Effectiveness Research is to assist consumers, clinicians, purchasers and policy makers to make informed decisions that will improve health care at both the individual and population levels.
More specifically, the health science research program helps people and their caregivers communicate and make informed health care decisions, allowing their voices to be heard in assessing the value of health care options.
Although not limited to, the two main application areas are oncology and cardiovascular disease. The University of Twente thereby has specific expertise in developing methodology for the evaluation of personalized or precision medicine technologies, such as molecular diagnostics and imaging markers. The research program in Twente has its strengths in the evaluation and development of personalized e-Health technologies, healthcare operations research and early Health Technology Assessment.
Early Health Technology Assessment, including early Health Economic Modeling, is increasingly promoted as an approach to determine added value of potential new technologies early in the development pipeline. Such assessment would be useful to (1) decide about further development of the technology, (2) to define minimum performance thresholds for the new technology compared to currently available technologies and (3) to support pricing and reimbursement in early stages of development. It thereby considers existing regulatory requirements in several countries as well as mechanisms for obtaining reimbursement depending on the added value produced. Early Health Technology Assessment deviates from mainstream Health Technology Assessment as it primarily informs R&D instead of government (agencies) deciding about coverage.